THE ONLY 8-WEEK PANGEOTYPIC TREATMENT FOR TREATMENT-NAÏVE, NON-CIRRHOTIC PATIENTS1
NO CHANGE IN DOSING REQUIRED FOR RENALLY IMPAIRED PATIENTS
- MAVYRET is contraindicated in patients with severe hepatic impairment (Child-Pugh C) and is not recommended in patients with moderate hepatic impairment (Child-Pugh B)
- Due to higher rates of virologic failure and treatment-emergent drug resistance, the data do not support treatment of GT 1 infected patients who are both NS3/4A protease inhibitor and NS5A inhibitor-experienced.
*In clinical trials, subjects were treated with prior regimens containing LDV and SOF or DCV with peglFN and RBV.